Staidson Beijing BioPharmaceuticals Co., Ltd. announced earnings results for the nine months ended September 30, 2021. For the nine months, the company announced total revenue was CNY 426.311 million compared to CNY 296.202 million a year ago. Operating loss was CNY 126.074 million compared to CNY 81.385 million a year ago. Net loss was CNY 125.811 million compared to CNY 98.228 million a year ago. Basic loss per share from continuing operations was CNY 0.27 compared to CNY 0.21 a year ago.